P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $69.54
    -0.55 (-0.78%)

    Market Cap: $5.85B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    +37.26%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.31
    Range$0.15 - $0.48
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$0.47+52.7%
    60d ago$0.47+52.7%
    30d ago$0.54+73.1%
    7d ago$0.31+0.0%
    Current$0.31
    Revenue Consensus
    $302M
    Range$274M - $322M
    12 analysts
    Dec 31, 2026
    EPS Consensus$1.39
    Range$0.95 - $1.61
    3 analysts
    Revenue Consensus
    $429M
    Range$364M - $475M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.39---
    Sep 26EST
    		-$0.31---
    Jun 26
    		$0.92$-0.17+641.18%Beat+210.8%
    Mar 26
    		$-0.03N/A+93.18%Beat-100.3%
    Dec 25
    		$-1.80$-0.40-350.00%Miss-426.9%
    Sep 25
    		$0.19N/A+117.12%Beat+114.0%
    Jun 25
    		$-0.83$-1.07+22.43%Beat+34.6%
    Mar 25
    		$10.04$-0.70+1534.29%Beat+936.7%
    Dec 24
    		$-0.34$-0.65+47.45%Beat-42.3%
    Sep 24
    		$-1.36$-1.66+18.07%Beat+22.3%
    Jun 24
    		$-1.27$-0.95-33.68%Miss+19.6%
    Mar 24
    		$-1.20$-1.10-9.09%Miss+36.2%
    Dec 23
    		$-0.24N/A-148.00%Miss+87.3%
    Sep 23
    		$-1.75$-1.55-12.90%Miss-14.4%
    Jun 23
    		$-1.58$-1.71+7.60%Beat+25.8%
    Mar 23
    		$-1.88$-1.63-15.34%Miss-5.6%
    Dec 22
    		$-1.89$-1.59-18.87%Miss+6.9%
    Sep 22
    		$-1.53$-1.26-21.43%Miss+19.0%
    Jun 22
    		$-2.13$-1.48-43.92%Miss-26.8%
    Mar 22
    		$-1.78$-1.66-7.23%Miss+2.7%
    Dec 21
    		$-2.03$-1.65-23.03%Miss-88.0%
    Sep 21
    		$-1.89$-1.89+0.00%Beat-83.5%
    Jun 21
    		$-1.68$-1.82+7.69%Beat+6.7%
    Mar 21
    		$-1.83$-1.62-12.96%Miss-1.1%
    Dec 20
    		$-1.08$-0.94-14.89%Miss+21.2%
    Sep 20
    		$-1.03$-0.45-128.89%Miss-15.7%
    Jun 20
    		$-1.80$-1.56-15.38%Miss-176.9%
    Mar 20
    		$-1.81$-1.33-36.09%Miss-98.9%
    Dec 19
    		$-1.37$-0.71-92.96%Miss-136.2%
    Sep 19
    		$-0.89$-0.88-1.14%Miss+16.0%
    Jun 19
    		$-0.65$-0.61-6.56%Miss-209.5%
    Mar 19
    		$-0.91$-0.68-33.82%Miss-97.8%
    Dec 18
    		$-0.58$-0.32-81.25%Miss-2033.3%
    Sep 18
    		$-1.06$-0.49-116.33%Miss-29.3%
    Jun 18
    		$-0.21N/A+52.27%Beat+52.3%
    Mar 18
    		$-0.46$-0.38-21.05%Miss+45.9%
    Dec 17
    		$0.03N/A+121.43%Beat+103.8%
    Sep 17
    		$-0.82$-0.67-22.39%Miss+20.4%
    Jun 17
    		$-0.44$-0.86+48.84%Beat-
    Mar 17
    		$-0.85$-0.93+8.60%Beat-
    Dec 16
    		$-0.78$-1.07+27.10%Beat-
    Sep 16
    		$-1.03$-1.15+10.43%Beat-

    Key Metrics

    Valuation
    P/E Ratio-96.58EV/EBITDA25.71x
    Price/FCF-145.36xFCF Yield-0.69%
    Profitability
    Profit Margin-3.81%Operating Margin41.30%
    ROE-7740.00%ROIC18.05%
    Financial Health
    Debt/Equity-3.57xInterest CoverageN/A
    Current Ratio3.39xQuick Ratio3.28x
    Trading Statistics
    Beta0.55Avg Volume888.30K
    52-Week High$90.8752-Week Low$49.38

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$71.53
    SMA 20$71.76
    SMA 50$76.80
    SMA 200$73.44
    EMA 10$71.35
    EMA 20$72.24
    EMA 50$73.90
    EMA 200$71.13

    MACD

    Line: -1.26Signal: -1.31Hist: 0.04

    ADX

    ADX: 19.5+DI: 16.5-DI: 29.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down16.0
    PSAR$74.33

    Bollinger Bands

    Upper Band$75.09
    Lower Band$68.44
    %B Position927%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    39.9

    Momentum Oscillators

    Stoch %K36.2
    Stoch %D51.0
    Williams %R-75.5
    ROC (10d)-4.6%
    Momentum-3.34
    CCI (20d)-106.6
    MFI (14d)34.7

    Volatility Measures

    ATR (14d)$2.42(3.5%)
    StdDev (20d)1.66
    Hist Vol31.6%(Moderate)

    Volume Flow

    VWAP$69.57
    OBV61.9M
    AD Line18.7M
    CMF (20d)0.157

    Volume Metrics

    Avg Vol (20d)864.3K
    Vol Ratio1.0x
    VWMA (20d)$71.71

    Pivot Points

    R3$73.06
    R2$72.28
    R1$71.18
    Pivot Point$70.40
    S1$69.30
    S2$68.52
    S3$67.42

    Advanced Oscillators

    TSI-13.93
    Ultimate Osc53.8
    KST-65.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$360.52M$272.55M$164.68M$211.01M$178.88M$1.18B$213.17M$196.79M$186.70M$210.12M$307.06M$196.58M
    Cost of Revenue$19.92M$28.03M$-24,282,000$0$11.42M$0$27.13M$0$15.53M$14.74M$-36,368,000$9.49M
    Gross Profit$340.60M$244.52M$188.96M$211.01M$167.46M$1.18B$186.04M$196.79M$171.18M$195.38M$343.42M$187.08M
    Operating Expenses$191.62M$199.56M$260.31M$207.99M$202.41M$205.87M$348.43M$251.30M$211.40M$240.83M$337.60M$305.25M
    R&D$99.15M$100.87M$133.13M$100.16M$112.99M$108.97M$124.77M$161.41M$132.17M$116.13M$121.35M$164.21M
    SG&A$80.63M$86.18M$96.87M$84.05M$85.26M$80.96M$84.68M$73.46M$69.50M$73.27M$76.29M$80.89M
    Operating Income$148.98M$44.96M$-71,349,000$3.02M$-34,957,000$970.23M$-162,389,000$-54,510,000$-40,218,000$-45,453,000$5.82M$-118,164,000
    Interest Income$-48,481,000$-49,030,000$-55,188,000$-32,592,000$-30,358,000$-34,092,000$58.84M$-41,609,000$-43,490,000$-40,834,000$-44,274,000$-28,160,000
    Interest Expense$51.43M$47.42M$67.73M$0$36.09M$40.40M$0$0$0$0$137.56M$0
    Income Before Tax$97.55M$-2,462,000$-139,083,000$-23,074,000$-71,052,000$929.83M$-94,699,000$-97,991,000$-85,733,000$-84,696,000$-157,051,000$-166,590,000
    Income Tax Expense$14.05M$347,000$-4,118,000$-38,970,000$-6,203,000$63.27M$-28,813,000$8.66M$13.45M$6.88M$-1,259,000$-33,620,000
    Net Income$83.50M$-2,809,000$-134,965,000$15.90M$-64,849,000$866.56M$-65,886,000$-106,654,000$-99,179,000$-91,576,000$-155,792,000$-132,970,000
    EBITDA$158.13M$58.17M$-75,730,000$14.83M$-37,365,000$969.13M$-149,050,000$-52,550,000$-38,226,000$8.13M$103.67M$-75,803,000
    EBIT$146.03M$46.57M$-83,895,000$9.52M$-40,694,000$963.92M$-153,539,000$-56,382,000$-42,243,000$-43,862,000$24.78M$-138,430,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PTCT

    News

    Ptc Therapeutics Announces New Sephience Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as Well as Consistent Favorable Safety Profile

    PTC Therapeutics announced new scientific data for Sephience (sepiapterin) will be presented at the 2026 SSIEM Annual Symposium. The data highlights Sephience's benefits for individuals with phenylketonuria (PKU), showing sustained metabolic control, significant diet liberalization, and a consistent favorable safety profile, including for those with classical PKU and high baseline Phe levels. Sephience, a natural precursor of BH4, is approved in multiple regions and effectively reduces blood phenylalanine levels across a broad range of PKU patients.

    marketscreener.com•8/24/26•
    Bullish

    PTCT Looks 84.3% Overvalued on GF Value™

    PTC Therapeutics (

    GuruFocus•8/24/26•
    Somewhat-Bearish

    PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

    PTC Therapeutics announced new data on Sephience (sepiapterin) for phenylketonuria (PKU), to be presented at the SSIEM Symposium. The data reinforces Sephience's benefits in lowering phenylalanine, enabling diet liberalization, and maintaining metabolic control across all PKU patient subgroups, including those with classical PKU, with a consistent favorable safety profile. Analyses from the AMPLIPHY study and real-world data show significant improvements in blood Phe levels and dietary freedom for patients.

    PR Newswire•8/24/26•
    Bullish

    PTC Therapeutics director Schmertzler disposes of $1.8m in stock

    Michael Schmertzler, a director at PTC Therapeutics, Inc. (NASDAQ:PTCT), recently sold approximately $1.8 million worth of common stock in mid-August through several transactions. These sales, conducted under a Rule 10b5-1 trading plan, occurred between August 19 and August 20, 2026, with share prices ranging from $70.78 to $73.67. This comes as analysts predict profitability for the company this year, with recent strong Q2 2026 results surpassing expectations.

    Investing.com•8/22/26•
    Somewhat-Bullish

    Price to earnings forward of PTC Therapeutics, Inc. – NASDAQ:PTCT

    This article provides a financial data point for PTC Therapeutics, Inc. (NASDAQ: PTCT), specifically its forward price-to-earnings ratio. The content itself is very minimal, presenting only the company name, stock ticker, and the financial metric without any further details or analysis. The page appears to be a stub or a data point from a larger financial platform.

    TradingView•8/22/26•
    Neutral

    Frequently Asked Questions About PTCT

    Does PTCT pay dividends?
    PTC Therapeutics Inc (PTCT) does not currently pay a regular dividend.
    What is PTCT's market cap?
    PTC Therapeutics Inc (PTCT) has a market capitalization of $5.85B with a current stock price of $69.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In